Targets › CCK2R
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: the race on CCK2R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University Hospital, Basel, Switzerland | 177Lu-PP-F11N Cholecystokinin-2 receptor ligand (gastrin analogue) | CCK2R | Phase 1 | Thyroid Cancer, Medullary | Apr 2027 |
Thyroid Cancer, Medullary (1)
small molecule (1)
University Hospital, Basel, Switzerland (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.